Drawing the Line: The Ethics of Using Peptides for Recovery

Two lifters, two different questions

Picture a powerlifter who partially tears a pec on a heavy bench press. He's facing months of rehab, and he decides to add BPC-157 and TB-500 to it. He isn't trying to get stronger than he was before the injury. He wants to get back to where he was.

Now picture a second lifter with no injury. Five hard sessions a week leave him worn down, so he starts CJC-1295 with ipamorelin, hoping for deeper sleep and a bigger nightly growth hormone pulse. His plan is to add a sixth training day.

Most people sense that these cases differ. The first lifter is reaching for therapy, the second for enhancement, and that distinction does real work in sport ethics and anti-doping rules. It doesn't settle everything, though: both lifters are using compounds with very little human evidence behind them, usually bought outside normal medical channels.

Healing an injury: the strongest case

Using a compound to recover from a specific injury, with the goal of returning to normal function, is the easiest use to defend. Ethically, it sits close to physical therapy, an approved medicine, or a clinician-performed procedure such as a platelet-rich plasma (PRP) injection. The aim is restoration, not a new ceiling.

The analogy breaks down on evidence. A 2025 systematic review aimed at orthopaedic sports medicine included 36 studies of BPC-157: 35 were preclinical and one was clinical, and the authors found no clinical safety data. In rodents, BPC-157 has been linked to better healing of muscle, tendon, ligament and bone, along with signs of angiogenesis (new blood vessel growth) and lower inflammatory markers. In people, the record as of October 2026 is a few small uncontrolled pilots. The most recent, published in 2025, gave two adults IV infusions of 10 mg and then 20 mg, and neither reported side effects. On this site's scale, that's emerging evidence.

TB-500 has less. It's a seven-amino-acid fragment of thymosin beta-4, first characterized by an anti-doping lab that analyzed a product suspected of doping use. FDA says it has found no human exposure data for the fragment, and trials of full-length thymosin beta-4 don't carry over to it. We rate it preliminary. Vendors often call it "systemic", but nobody has measured how it distributes in the human body.

So the goal is legitimate, but the tool is experimental. Someone using BPC-157 for a torn pec is running an uncontrolled experiment on themselves, which an informed adult can reasonably choose to do. Our overview of peptides and muscle recovery covers what the studies measured, and our comparison with other recovery methods sets peptides beside options with more human data.

When recovery becomes enhancement

The second lifter isn't repairing damage. He wants to recover from normal training stress faster than his body would on its own, so he can do more work. That's recovery in one sense and enhancement in another, because the point is to raise his baseline rather than restore it.

The wrinkle is that the edge may be smaller than he expects. Growth hormone secretagogues and GHRH analogues reliably raise growth hormone, and with repeated dosing IGF-1, but trials have rarely shown the outcomes users are after:

• In a 2-year randomized trial of 65 healthy adults aged 60-81, oral MK-677 (25 mg daily) raised fat-free mass by about 1.1 kg compared with a small loss on placebo. Strength and function didn't change, fasting glucose rose, and insulin sensitivity fell.
• In 11 healthy men aged 64-76, nightly sermorelin injections (2 mg) for 6 weeks raised nighttime growth hormone but didn't change IGF-1, body composition or glucose. Two of six strength measures improved.

Neither trial studied young lifters, and we found no trial of ipamorelin with CJC-1295 for training recovery. Users commonly report sleeping better on these compounds; we couldn't find a controlled study that measured sleep in trained athletes. The second lifter clearly intends to gain an edge. Whether he gets one is an open question, and rulebooks respond to the intent and the substance, not to the size of the effect.

Context decides most of it

Training for yourself

If you don't compete and don't sell anything based on your physique, the ethics are mostly personal. Fairness isn't really at stake; safety and product quality are. Gray-market vials aren't made to drug-manufacturing standards, and the 2025 review lists unregulated manufacturing and contamination among the ways harm could occur. A doctor reading your bloodwork also needs to know what you're using.

Tested athletes

Here the rule is written down. As of October 2026, WADA's 2026 Prohibited List bans every compound in the two examples above at all times, in and out of competition:

• BPC-157 is named in S0, non-approved substances.
• TB-500 is named in S2.3, growth factors ("Thymosin-β4 and its derivatives e.g. TB-500").
• CJC-1295, sermorelin and tesamorelin are named in S2.2.4 as GHRH analogues, and ipamorelin and MK-677 in S2.2.4 as growth hormone secretagogues.

The list bans the substance whatever the reason for using it. Genuine medical need goes through a Therapeutic Use Exemption (TUE), and WADA's criteria turn the therapy-versus-enhancement line into a rule: the substance must treat a diagnosed condition and give no enhancement beyond a return to normal health. It also has to be an indicated treatment with no reasonable permitted alternative. BPC-157 and TB-500 aren't approved for any condition, so it's hard to see how either could pass that test (our reading; we found no published TUE decision for either). For a tested lifter with a torn pec, the healing rationale doesn't create an exception.

Natural bodybuilding

Drug-free federations write their own banned lists and testing rules, so the specific federation's policy is the one that counts. The "natural" label also carries a promise to competitors and the audience that goes beyond any single list. A peptide missing from one federation's list doesn't make its use consistent with that promise.

Coaches and influencers

When someone sells coaching or products partly on the strength of their own physique, followers treat that physique as evidence. Leaving out peptide use misleads them about what training and diet alone can do. Describing a stack as if it were proven adds a second problem, because it passes an experiment off as a protocol.

Medical supervision doesn't settle it

Many users describe their use as "under medical supervision". For recovery peptides, that often means a cash-pay longevity or performance clinic rather than a doctor treating a diagnosed injury with an approved drug. Supervision does bring safety benefits, such as baseline bloodwork and someone watching for side effects.

It doesn't change the compound's status. As of October 2026, BPC-157 and the TB-500 fragment sit in FDA's "nominated but withdrawn" table and aren't on the 503A bulks list that US pharmacies compound from. FDA's compounding advisory committee reviewed both in July 2026; FDA's own briefing papers recommended against adding them, and advisers reportedly voted narrowly in favor. As of October 2026, FDA hasn't proposed a rule. A prescription doesn't make either one an approved medicine, and it doesn't create a TUE.

Approvals are narrow. Tesamorelin is a prescription medicine approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin, which users often describe getting through telehealth, was formerly FDA-approved as Geref for growth hormone deficiency in children; it was discontinued in 2008 and its approvals were withdrawn in 2009, not for safety or effectiveness reasons. That approval never covered adult recovery.

Seen this way, a performance-clinic prescription is a harm-reduction step. It can make the experiment safer, but it's still an experiment.

Questions worth asking yourself

1. Am I restoring or exceeding? Fixing a specific injury to get back to normal is different from building recovery beyond what training alone allows.
2. Whose rules apply to me? If you're tested under the World Anti-Doping Code or by a drug-free federation, the answer is already set, and an injury doesn't change it.
3. Who relies on my honesty? Competitors, clients and followers who believe your results come from training and diet alone are owed disclosure.
4. Do I understand the evidence? For BPC-157 it's mostly rodent data; for TB-500, essentially no human data. Our page on long-term effects on muscle recovery covers what's known about sustained use.

What we still don't know

• Whether BPC-157 helps human injuries heal. As of October 2026, no controlled human trial has published results. A University of Arkansas Phase 1 study of BPC-157 after rotator cuff repair (NCT07803250, about 30 participants planned) is registered to start in January 2027.
• What FDA does after the July 2026 committee meeting. A rule adding BPC-157 or TB-500 to the 503A list would change how US clinics can source them. It wouldn't make either an approved drug, and it wouldn't change WADA's list.
• Whether growth hormone-raising peptides improve recovery in young, trained people. The longer human trials enrolled older adults, and none measured training recovery directly.